Results 11 to 20 of about 1,998,403 (289)

Negative Immune Checkpoint Inhibitors

open access: yesPharmaceutics
Checkpoint inhibitors are a modern therapeutic approach for treating various types of cancer, metabolic diseases, and chronic infections. The main goal of this therapy is to specifically unlock the immune system, allowing it to recognize and eliminate ...
Magda Drewniak-Świtalska   +2 more
doaj   +4 more sources

Immune checkpoint inhibitors [PDF]

open access: yesJournal of Cell Biology, 2019
Hui details the cell biology underlying the action of immune checkpoint inhibitors.
Pawel Kalinski, Per Basse
core   +9 more sources

Nephrotoxicity of checkpoint inhibitors; a current challenge [PDF]

open access: yesJournal of Nephropharmacology
Immune checkpoint inhibitors work by blocking the "checkpoint" mechanism that tumors use to hide from the immune system, therefore also weakening the immune system.
Samaneh Zandifar   +4 more
doaj   +3 more sources

Cardiotoxicity of immune checkpoint inhibitors [PDF]

open access: yesESMO Open, 2017
Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically been a relevant issue. In addition, targeted therapies and biological molecules can also induce cardiotoxicity. Immune checkpoint inhibitors are a novel class of anticancer drugs, distinct from targeted or tumour type-specific therapies.
VARRICCHI, GILDA   +7 more
openaire   +4 more sources

Immune checkpoint inhibitors [PDF]

open access: yesJournal of Experimental Medicine, 2021
Three papers by James Allison and Tasuku Honjo published in JEM between 1995 and 2000 crystallized seminal insights into the role of CTLA-4 and PD-1 in immunosuppression (Krummel and Allison. 1995. J. Exp. Med.https://doi.org/10.1084/jem.182.2.459; van Elsas et al. 1999. J. Exp. Med.https://doi.org/10.1084/jem.190.3.355; Freeman et al. 2000. J.
Kroemer, Guido, Zitvogel, Laurence
  +6 more sources

Immune Checkpoint Inhibitors in Gliomas

open access: yesCurrent Oncology Reports, 2017
Malignant gliomas result in disproportionately high morbidity and mortality compared with other primary tumors, and progression of disease is inevitable. Novel therapies to improve outcomes are needed and immune checkpoint inhibitors hold significant promise.A limited body of preclinical evidence suggests that checkpoint inhibitors may be effective ...
Aaron C, Tan   +2 more
openaire   +3 more sources

Immune Checkpoint Inhibitors and the Heart [PDF]

open access: yesFrontiers in Cardiovascular Medicine, 2021
Immune checkpoint inhibitors (ICIs) represent a break-through treatment for a large number of cancer types. This treatment is increasingly being recommended. ICIs are prescribed for primary tumours and for metastases, adjuvant/neo-adjuvant therapy.
Diana Larisa Mocan-Hognogi   +11 more
openaire   +3 more sources

Ionic modulation of immune checkpoint proteins [PDF]

open access: yes, 2019
Despite extensive basic and clinical research on immune checkpoint regulatory pathways, little is known about the effects of the ionic tumour microenvironment on immune checkpoint expression and function.
Lawrence, Samantha   +3 more
core   +5 more sources

Immune Checkpoint Inhibitors [PDF]

open access: yes, 2023
Immune Checkpoint Inhibitors - New Insights and Recent Progress explores a vast array of subjects related to immune checkpoint inhibitors and presents novel insights in this emerging field.

core   +1 more source

Immune Checkpoint Inhibitors [PDF]

open access: yesJAMA Oncology, 2015
Undoubtedly the discovery of immune checkpoints such as CTLA-4 and PD-1 has been crucial to the development of cancer immunotherapy. Although these molecules were originally discovered as molecules playing a role in T cell activation or apoptosis, subsequent preclinical research showed their important role in the maintenance of peripheral immune ...
John B A G, Haanen, Caroline, Robert
openaire   +3 more sources

Home - About - Disclaimer - Privacy